Effect of a long-acting somatostatin analogue (bim23014) on proliferative diabetic retinopathy: A pilot study

52Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.
Get full text

Abstract

A pilot study on the use of a continuous infusion of somatostatin, by subcutaneous pumps in the management of proliferative diabetic retinopathy is reported. Two patients out of eight with proliferative retinopathy demonstrated improvement. One patient demonstrated regression of disc new vessels and the other a reduced area of retinal capillary non-perfusion, both demonstrated by fluorescein angiography. Control patients showed worsening of fluorescein leakage over the observation period of four to six weeks whereas the other six patients given the somatostatin infusion did not demonstrate any deterioration.The mechanism of action of somatostatin in this study is unknown but it is thought to have direct anti-angiogenic properties as well as inhibiting growth hormone secretion. © 1991, College of Ophthalmologists. All right reserved.

Cite

CITATION STYLE

APA

McCombe, M., Lightman, S., Eckland, D. J., Hamilton, A. M., & Lightman, S. L. (1991). Effect of a long-acting somatostatin analogue (bim23014) on proliferative diabetic retinopathy: A pilot study. Eye (Basingstoke), 5(5), 569–575. https://doi.org/10.1038/eye.1991.99

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free